- Home
- RDVT vs LXRX Comparison
RDVT vs LXRX Comparison
Compare RDVT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDVT | LXRX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.8M | 547.4M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RDVT | LXRX |
|---|---|---|
| Price | $40.52 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | $4.15 |
| AVG Volume (30 Days) | 81.9K | ★ 2.3M |
| Earning Date | 06-09-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.00 | 77.78 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $90,252,000.00 | $49,803,000.00 |
| Revenue This Year | $14.77 | N/A |
| Revenue Next Year | $14.48 | $22.16 |
| P/E Ratio | $47.49 | ★ N/A |
| Revenue Growth | 20.03 | ★ 60.24 |
| 52 Week Low | $32.23 | $0.32 |
| 52 Week High | $64.14 | $1.83 |
Technical Indicators
Market Signals| Indicator | RDVT | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 63.28 |
| Support Level | $39.89 | $1.08 |
| Resistance Level | $52.21 | $1.83 |
| Average True Range (ATR) | 2.38 | 0.12 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 8.50 | 75.34 |
Price Performance
Historical ComparisonAbout RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.